However, masitinib, a multikinase inhibitor (with activity against Kit, Lyn, PDGFR/Abl/Fms/Src, and FGFR3, some of which may signal downstream of the ERBB/HER system [48]) has shown activity in an mSOD1-mutant rodent model of ALS [49] and has demonstrated potential efficacy in a phase 2/3 clinical trial in ALS (NCT02588677) [50], a trial in primary progressive multiple sclerosis or nonactive secondary progressive multiple sclerosis [51], and Alzheimer’s disease [52, 53]. This evidence concerns the gene SRC and amyotrophic lateral sclerosis.